Predictive Oncology Reports Second Quarter 2023 Financial Results and Provides Business Update

Rhea-AI Summary

Predictive Oncology (POAI) reported a net loss of $3.9 million on total net revenue of $0.5 million for the second quarter of 2023. The company initiated strategic collaborations, delivered a presentation at the Bio International Convention, and relocated its corporate headquarters to Pittsburgh, PA. Predictive Oncology's financial summary for Q2 2023 includes $14.8 million in cash and cash equivalents, $14.7 million in Stockholder’s Equity, and a loss per common share of $0.98. The company recorded revenue of $490,110 in Q2 2023, with gross profit margin increasing to 67%. However, G&A expenses, operations expenses, and sales and marketing expenses all increased compared to the same period in 2022.

Positive

• None.

Negative

• Predictive Oncology recorded a net loss of $3.9 million for the second quarter of 2023, which is a negative financial aspect. G&A expenses, operations expenses, and sales and marketing expenses all increased compared to the same period in 2022, indicating rising costs for the company.

Company to host investor call and webcast today, August 10th, at 5:30pm EDT

PITTSBURGH, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI), a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, CLI laboratory and GMP facility, to accelerate oncologic drug discovery and enable drug development, today reported financial and operating results for the three and six months ended June 30, 2023, and provided a corporate update. The company reported a net loss of $3.9 million on total net revenue of $0.5 million for the second quarter 2023.

Q2 2023 and Recent Highlights:

• Initiated PEDAL-Cancer Research Horizons collaboration for the analysis of drug compounds;
• Initiated strategic collaboration with Cvergenx to identify novel molecules and compounds and the repurposing of radioprotective or radiosensitizing drugs;
• Delivered a presentation on the importance of addressing patient heterogeneity in drug discovery and the advantages of leveraging active machine learning at the Bio International Convention in Boston in June; met with more than 30 biopharmaceutical development customer prospects and further expanding Predictive Oncology’s sales pipeline;
• Established new Business Advisory Board and announced first two appointments: Dr. Bernard Harris and Andrew Einhorn;
• Appointed pharma, biotech and digital health industry veteran, Dr. Veen Rao, to the Company’s Board of Directors;
• Relocated corporate headquarters to Pittsburgh, PA from Eagan, MN.

“We are very pleased with the steady progress that we have made since our last quarterly update, both advancing current PEDAL relationships with CRH, Cvergenx and others, while in parallel building our pipeline as more drug developers – both biopharmaceutical companies as well as research institutions – see the value that only Predictive Oncology can bring to the early drug discovery process,” said Raymond F. Vennare, Chief Executive Officer and Chairman of Predictive Oncology. “With our unique set of assets and capabilities that clearly set us apart from other AI-focused drug discovery companies, including our extensive biobank of more than 150,000 tumor samples, combined with our CLIA lab, we can validate our predictions in wet lab experiments in a setting that introduces patient heterogeneity into the earliest phases of drug discovery. We are the only company capable of doing this, and the results of these experiments can significantly increase the chances of later-stage clinical success by our customers.”

“The tangible impact of our presence at Bio International this year was measurable. The sustained exposure and global reach afforded by conferences like this will prove critical to our long-term success as we continue to raise awareness of Predictive Oncology as the ‘partner of choice’ for drug developers looking to streamline their drug discovery efforts with AI and machine learning capabilities. I am very pleased with our progress to date and look forward to meaningful developments with current and prospective customers in the back half of the year and into 2024,” Mr. Vennare concluded.

Q2 2023 Financial Summary:

• Concluded the second quarter of 2023 with $14.8 million in cash and cash equivalents, compared to $22.1 million as of December 31, 2022, and $14.7 million in Stockholder’s Equity, compared to $21.8 million as of December 31, 2022.
• Loss per common share for Q2 2023 was $0.98, as compared to $2.89 for the second quarter of 2022.

Q2 2023 Financial results

• Predictive Oncology recorded revenue of $490,110 in the second quarter of 2023, compared to $371,591 in 2022. Sales of Streamway related products and services by our Eagan operating segment were responsible for the majority of the revenue.
• Gross profit margin increased to 67% during the three months ended June 30, 2023 as compared to 64% in the comparable period in 2022 due to sales mix and higher margins on disposables for Streamway machines.
• G&A expenses increased by $352,831 to $2,704,527 for the three months ended June 30, 2023, compared to $2,351,696 for the same period in 2022. The increase was primarily due to increased investor relations fees related to the reverse stock split, office rent and other general and administrative expenses.
• Operations expense increased by $83,929 to $993,042 for the three months ended June 30, 2023 compared to $909,113 for the comparable three months ended in 2022, primarily due to higher cloud computing expenses, offset by decreases in expenses related to the closure of the offices of the Company’s former wholly-owned subsidiaries.
• Sales and marketing expenses increased by $158,081 for the three months ended June 30, 2023, to $429,103, compared to $271,022 for the same period in 2022. The increase was due primarily due to the increase in marketing and business development staff hired after June 20, 2022.
• Net cash used in operating activities was $7,002,033 and $6,427,806 for the six months ended June 30, 2023 and June 30, 2022, respectively. Cash used in operating activities increased in the 2023 period primarily due to an increase in operating expenses and changes in working capital.

Conference call and webcast details:

Predictive Oncology management will host an investor conference call and webcast today, August 10^th, at 5:30pm EDT.

To participate in the call, investors and analysts should dial 1-877-407-3982 (domestic) or 1-201-493-6780 (international) and reference conference ID 13739784.

To access the Call Me™ feature, which eliminates the need to wait for a call operator, please click here.

The live webcast of the call can be accessed here.

Forward-Looking Statements:

Certain matters discussed in this release contain forward-looking statements. These forward-looking statements reflect our current expectations and projections about future events and are subject to substantial risks, uncertainties and assumptions about our operations and the investments we make. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future revenue and financial performance, projected costs, prospects, plans and objectives of management are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “would,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Our actual future performance may materially differ from that contemplated by the forward-looking statements as a result of a variety of factors including, among other things, factors discussed under the heading “Risk Factors” in our filings with the SEC. Except as expressly required by law, the Company disclaims any intent or obligation to update these forward-looking statements.

Investor Relations Contact: 
Tim McCarthy, CFA
LifeSci Advisors, LLC 
tim@lifesciadvisors.com

PREDICTIVE ONCOLOGY INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)
		June 30, 2023				December 31, 2022
ASSETS
Current assets:
Cash and cash equivalents		$	14,763,745			$	22,071,523
Accounts receivable			430,849				331,196
Inventories			393,698				430,493
Prepaid expense and other assets			381,233				526,801
Total current assets			15,969,525				23,360,013
Property and equipment, net			1,548,805				1,833,255
Intangibles, net			266,183				253,865
Lease right-of-use assets			3,008,397				211,893
Other long-term assets			174,096				75,618
Total assets		$	20,967,006			$	25,734,644
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable		$	1,013,481			$	943,452
Accrued expenses and other liabilities			1,650,300				2,229,075
Derivative liability			5,572				13,833
Contract liabilities			627,896				602,073
Lease liability			466,087				94,237
Total current liabilities			3,763,336				3,882,670
Lease liability – net of current portion			2,498,613				86,082
Total liabilities			6,261,949				3,968,752
Stockholders’ equity:
Total stockholders' equity			14,705,057				21,765,892
Total liabilities and stockholders' equity		$	20,967,006			$	25,734,644

                      

PREDICTIVE ONCOLOGY INC. CONDENSED CONSOLIDATED STATEMENTS OF NET LOSS (Unaudited)
		Three Months Ended June 30,								Six Months Ended June 30,
			2023				2022				2023				2022
Revenue		$	490,110			$	371,591			$	730,005			$	686,159
Cost of goods sold			159,761				134,075				279,900				243,518
Gross margin			330,349				237,516				450,105				442,641
General and administrative expense			2,704,527				2,351,696				5,040,511				4,775,347
Operations expense			993,042				909,113				1,871,560				1,800,184
Sales and marketing expense			429,103				271,022				799,340				575,489
Loss on impairment of goodwill			-				7,231,093				-				7,231,093
Loss on impairment of property and equipment			162,905				-				162,905
Total operating loss			(3,959,228	)			(10,525,408	)			(7,424,211	)			(13,939,472	)
Other income			28,552				41,047				70,780				83,477
Other expense			-				(2,217	)			-				(3,206	)
Gain on derivative instruments			7,308				95,254				8,261				97,162
Net loss		$	(3,923,368	)		$	(10,391,324	)		$	(7,345,170	)		$	(13,762,039	)
Net loss per common share - basic and diluted		$	(0.98	)		$	(2.89	)		$	(1.84	)		$	(4.00	)
Weighted average shares used in computation – basic and diluted			3,996,512				3,589,684				3,982,384				3,441,546

 

FAQ

What were Predictive Oncology's financial results for the second quarter of 2023?

Predictive Oncology recorded a net loss of $3.9 million on total net revenue of $0.5 million for the second quarter of 2023. The company concluded the quarter with $14.8 million in cash and cash equivalents, $14.7 million in Stockholder’s Equity, and a loss per common share of $0.98.

What collaborations did Predictive Oncology initiate in Q2 2023?

In Q2 2023, Predictive Oncology initiated strategic collaborations with PEDAL-Cancer Research Horizons and Cvergenx to identify novel molecules and compounds and the repurposing of radioprotective or radiosensitizing drugs.

Where did Predictive Oncology relocate its corporate headquarters?

Predictive Oncology relocated its corporate headquarters to Pittsburgh, PA from Eagan, MN.

What was the gross profit margin for Predictive Oncology in Q2 2023?

The gross profit margin for Predictive Oncology increased to 67% during the three months ended June 30, 2023, compared to 64% in the comparable period in 2022 due to sales mix and higher margins on disposables for Streamway machines.

What were the operating expenses for Predictive Oncology in Q2 2023?

G&A expenses, operations expenses, and sales and marketing expenses all increased for Predictive Oncology in Q2 2023 compared to the same period in 2022.